

The Patient at the Centre of Clinical Research

Michal Rataj

23 November 2023



@eupatientsforum

“ A STRONG PATIENTS’ VOICE TO
DRIVE BETTER HEALTH IN EUROPE ”



Making research more patient-driven

From research *on/for* patients to research *with* patients

- Too many trials are on research questions – or measure outcomes – that are not the priority for patients
- Patients' preferences and priorities may be different from those of medical professionals, regulators, or industry
- Unmet needs are the driving force for patient groups to become active in medical research
 - Innovation that matters to patients → quality of life, the spectrum of patient-centred integrated care
 - Not only new therapies, but better therapies, better systems, social change...




Why does patient involvement matter?

- Advances in medicine are only possible with the voluntary participation of patients
- Patients provide the data and take the risks, benefit from the results
- Legitimacy, transparency and accountability
- Involvement also leads to better, more relevant research results
 - Better alignment of innovation with real unmet needs
 - Improved design of trials, e.g. endpoints that are relevant to patients
 - Improved information material
 - Better recruitment, fewer drop-outs
 - Researchers' assumptions are challenged: new insights, more context
 - Wider dissemination of findings
 - Potentially better regulatory outcomes

Patient involvement in research

To promote good practice requires engagement with all actors...

Impact of patient involvement is greater the earlier patients are involved – from priority setting stage to co-design & co-production of clinical research



Improving Patient Involvement in Medicines Research and Development: A Practical Roadmap. Geissler, Ryll, Leto, Uhlenhopp, Therapeutic Innovation & Regulatory Science (2017), doi: 10.1177/2168479017706405, and at www.eupati.eu

... But there is a need for a strong signal and guidance from regulators building on existing initiatives

- Clinical trials should better reflect the population that will ultimately use the medicine – a matter of **health equity!**
- Certain groups continue to be underrepresented which can undermine the quality of studies and hinder the full understanding of the benefit-risk profile
- Questions for reflection
 - Analyse countries' approaches and potential barriers at national level?
 - How to leverage new technologies and approaches to facilitate inclusivity? (digital technologies and social media, decentralised trials etc.)
 - Reviewing and broadening eligibility criteria?
 - Inclusive strategies for public outreach and information
 - The role of guidance, but also capacity-building and training of sponsors etc.

THANK YOU FOR YOUR ATTENTION!

Follow us on Social Media!



/europeanpatientsforum



/eupatient



/eupatientsforum



eu-patient.eu/blog

More information

www.eu-patient.eu

info@eu-patient.eu

“ A STRONG PATIENTS' VOICE TO
DRIVE BETTER HEALTH IN EUROPE ”